Gilead Sciences, Halozyme Therapeutics, Santarus, NPS Pharma, and InterMune Under AAAResearchReports.com Microscope

LONDON, July 2, 2013 /PRNewswire/ --

On Monday, July 1, 2013, shares in biotechnology companies ended mostly higher, tracking gains in the broader market. All three benchmark indices edged higher after investors digested better-than-expected U.S. economic data. The major movers in the industry included Gilead Sciences Inc. (NASDAQ: GILD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Santarus Inc. (NASDAQ: SNTS), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), and InterMune Inc. (NASDAQ: ITMN). AAAResearchReports.com has released full comprehensive research on GILD, HALO, SNTS, NPSP, and ITMN. These free technical analyses can be downloaded by signing up at:

http://www.aaaresearchreports.com/register/  

Shares in Gilead Sciences Inc. edged higher on Monday. The company's shares ended the day 0.75% higher at $51.65 after oscillating between $51.53 and $52.80. A total of 9.48 million shares were traded which is below the daily average volume of 11.08 million. In the last three months, Gilead's shares have gained 7.66%, thus outperforming the S&P 500. A free technical analysis on GILD available by signing up at:

http://www.AAAResearchReports.com/GILD070213.pdf

Halozyme Therapeutics Inc.'s stock fell sharply on Monday even as the broader market posted gains. The company's shares traded between $7.36 and $8.15 before finishing the day 3.27% lower at $7.69. A total of 3.60 million shares were traded which is more than double the daily average volume of 1.45 million. Despite the sharp decline on Monday, Halozyme's shares have gained 18.67% in the last three trading sessions and 43.20% in the last three months. Register today and access free research on HALO at:

http://www.AAAResearchReports.com/HALO070213.pdf

Shares in Santarus Inc. moved higher on Monday, closing at $21.28, up 1.09% from its previous closing price. The company's shares fluctuated between $21.18 and $22.06. A total of 831,052 shares were traded which is below the daily average volume of 1.30 million. Santarus' shares are currently trading near their 52-week high of $24.00. The stock is trading above its 50-day and 200-day moving averages. The free report on SNTS can be downloaded by signing up now at:

http://www.AAAResearchReports.com/SNTS070213.pdf

NPS Pharmaceuticals Inc.'s shares hit an intraday high of $16.13 before closing the day 5.56% higher at $15.95. A total of 1.74 million shares were traded which is below the daily average volume of 1.96 million. The company's shares are currently trading near their 52-week high of $16.47. A free report on NPSP can be accessed by registering at:

http://www.AAAResearchReports.com/NPSP070213.pdf

Shares in InterMune Inc. edged higher on Monday. The company's shares ended the day at $9.81, up 1.98%, after oscillating between $9.71 and $10.04. A total of 1.32 million shares were traded which is above the daily average volume of 1.15 million. In the last three months, InterMune's shares have gained 6.75%, hence outperforming the S&P 500. Register with AAA Research Reports and download research on ITMN for free at:

http://www.AAAResearchReports.com/ITMN070213.pdf

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED